Achieve Life Sciences, Inc. (ACHV) stock
ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as QUIT
$6.72+0.34 (+5.33%)
Close on Nov 6, 2026Market cap $708.81MP/E –Yield –
Achieve Life Sciences cash
Cash and short-term investments held at the end of each period.
Achieve Life Sciences's cash was $201.50M at Sep 30, 2026. For fiscal 2025 it was $36.40M, up 5.8% from the year before. Over ten years it grew -4.1% a year on average. The highest annual figure on record is $85.11M in fiscal 2010.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.40M | +5.8% |
| FY2024 | Dec 31, 2024 | $34.40M | +121.3% |
| FY2023 | Dec 31, 2023 | $15.55M | -37.2% |
| FY2022 | Dec 31, 2022 | $24.77M | -42.4% |
| FY2021 | Dec 31, 2021 | $43.02M | +20.0% |
| FY2020 | Dec 31, 2020 | $35.85M | +114.7% |
| FY2019 | Dec 31, 2019 | $16.70M | +14.4% |
| FY2018 | Dec 31, 2018 | $14.60M | +176.3% |
| FY2017 | Dec 31, 2017 | $5.28M | -79.3% |
| FY2016 | Dec 31, 2016 | $25.50M | -53.8% |
| FY2015 | Dec 31, 2015 | $55.20M | +17.2% |
| FY2014 | Dec 31, 2014 | $47.10M | +20.2% |
| FY2013 | Dec 31, 2013 | $39.20M | -48.0% |
| FY2012 | Dec 31, 2012 | $75.40M | +16.1% |
| FY2011 | Dec 31, 2011 | $64.93M | -23.7% |
| FY2010 | Dec 31, 2010 | $85.11M | +37.2% |
| FY2009 | Dec 31, 2009 | $62.05M | +714.5% |
| FY2008 | Dec 31, 2008 | $7.62M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $201.50M | +318.9% |
| Q2 FY2026 | Jun 30, 2026 | $187.30M | +238.1% |
| Q1 FY2026 | Mar 31, 2026 | $29.30M | +26.3% |
| Q4 FY2025 | Dec 31, 2025 | $36.40M | +5.8% |
| Q3 FY2025 | Sep 30, 2025 | $48.10M | +12.1% |
| Q2 FY2025 | Jun 30, 2025 | $55.40M | -9.6% |
| Q1 FY2025 | Mar 31, 2025 | $23.20M | -65.1% |
| Q4 FY2024 | Dec 31, 2024 | $34.40M | +121.3% |
| Q3 FY2024 | Sep 30, 2024 | $42.90M | +115.4% |
| Q2 FY2024 | Jun 30, 2024 | $61.30M | +144.5% |
| Q1 FY2024 | Mar 31, 2024 | $66.40M | +302.1% |
| Q4 FY2023 | Dec 31, 2023 | $15.55M | -37.2% |
| Q3 FY2023 | Sep 30, 2023 | $19.92M | +9.5% |
| Q2 FY2023 | Jun 30, 2023 | $25.07M | -14.7% |
| Q1 FY2023 | Mar 31, 2023 | $16.51M | -54.6% |
| Q4 FY2022 | Dec 31, 2022 | $24.77M | -42.4% |
| Q3 FY2022 | Sep 30, 2022 | $18.20M | -45.4% |
| Q2 FY2022 | Jun 30, 2022 | $29.38M | -30.1% |
| Q1 FY2022 | Mar 31, 2022 | $36.34M | +22.6% |
| Q4 FY2021 | Dec 31, 2021 | $43.02M | +20.0% |
| Q3 FY2021 | Sep 30, 2021 | $33.31M | +48.8% |
| Q2 FY2021 | Jun 30, 2021 | $42.00M | +246.8% |
| Q1 FY2021 | Mar 31, 2021 | $29.64M | +143.8% |
| Q4 FY2020 | Dec 31, 2020 | $35.85M | +114.7% |
| Q3 FY2020 | Sep 30, 2020 | $22.39M | +203.6% |
| Q2 FY2020 | Jun 30, 2020 | $12.11M | +15.9% |
| Q1 FY2020 | Mar 31, 2020 | $12.16M | +25.3% |
| Q4 FY2019 | Dec 31, 2019 | $16.70M | +14.4% |
| Q3 FY2019 | Sep 30, 2019 | $7.38M | -44.1% |
| Q2 FY2019 | Jun 30, 2019 | $10.45M | -31.6% |
| Q1 FY2019 | Mar 31, 2019 | $9.70M | +132.9% |
| Q4 FY2018 | Dec 31, 2018 | $14.60M | +176.3% |
| Q3 FY2018 | Sep 30, 2018 | $13.20M | +64.6% |
| Q2 FY2018 | Jun 30, 2018 | $15.28M | +9.8% |
| Q1 FY2018 | Mar 31, 2018 | $4.17M | +431.3% |
| Q4 FY2017 | Dec 31, 2017 | $5.28M | -79.3% |
| Q3 FY2017 | Sep 30, 2017 | $8.02M | – |
| Q2 FY2017 | Jun 30, 2017 | $13.92M | – |
| Q1 FY2017 | Mar 31, 2017 | $784.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $25.50M | – |
See a number that looks wrong?